A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

NCT03803761 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DRUG: Copanlisib
DRUG: Fulvestrant

Sponsor

National Cancer Institute (NCI)